Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MREO Mereo BioPharma Group PLC

0.22 (11.58%)
Last Updated: 11:28:39
Delayed by 15 minutes


Draw Mode:

Volume 701,890
Bid Price 2.11
Ask Price 2.12
News -
Day High 2.16


52 Week Range


Day Low 1.912
Company Name Stock Ticker Symbol Market Type
Mereo BioPharma Group PLC MREO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.22 11.58% 2.12 11:28:39
Open Price Low Price High Price Close Price Prev Close
1.95 1.912 2.16 1.90
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,042 701,890 $ 2.08 $ 1,460,295 - 0.4945 - 2.39
Last Trade Time Type Quantity Stock Price Currency
11:29:31 8 $ 2.11 USD

Mereo BioPharma Group PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 140.18M - 811k -34.2M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mereo BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MREO Message Board. Create One! See More Posts on MREO Message Board See More Message Board Posts

Historical MREO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.082.18041.861.96828,1110.041.92%
1 Month2.062.391.862.09984,1140.062.91%
3 Months1.392.391.071.741,256,9500.7352.52%
6 Months1.052.390.92011.461,378,5281.07101.9%
1 Year0.76832.390.49451.251,283,4041.35175.93%
3 Years2.384.71120.3012.011,645,137-0.26-10.92%
5 Years6.556.56590.3012.041,119,637-4.43-67.63%

Mereo BioPharma Description

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Your Recent History